國立高雄大學圖資館 |

Language: English

Back to Search results for [ subject:"Systematic biology." ]

Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology.
Author:	Doherty, Laura.
Published:	Ann Arbor : ProQuest Dissertations & Theses, 2021
Description:	186 p.
Notes:	Source: Dissertations Abstracts International, Volume: 83-05, Section: B.
Notes:	Includes supplementary digital materials.
Notes:	Advisor: Sorger, Peter;Buhrlage, Sara.
Contained By:	Dissertations Abstracts International83-05B.
Subject:	Systematic biology.
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28720041
ISBN:	9798496528863

Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology.
Doherty, Laura.

Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 186 p.

Source: Dissertations Abstracts International, Volume: 83-05, Section: B.

Thesis (Ph.D.)--Harvard University, 2021.

This item must not be sold to any third party vendors.

DUBs are dysregulated in cancer and other diseases, but there is much that is unknown about the specific substrates and pathways that individual DUBs regulate and their clinical utility remains incompletely explored. In this work, I present characterization of the functions and therapeutic potential of DUBs in oncology through pharmacological and genetic studies coupled with analysis of publicly available datasets. First, I used phenotypic screens using early small molecule DUB inhibitors and target deconvolution to identify promising DUB targets in acute myeloid leukemia (AML) and breast cancer (chapter II). Specifically, I identify USP10 as the DUB responsible for stabilizing the oncoprotein, FMS-like receptor tyrosine kinase-3 (FLT3), in AML, and I identify USP7 as a DUB with selective proliferative effects based on subtype in breast cancer. Next, I used targeted studies with USP7 inhibitors to understand the functions of USP7 important for transcription and proliferation as well as characterize the polypharmacology of commonly used USP7 inhibitors. (chapter III). I conclude that p53 is central to the impact of USP7 on both proliferation and the transcriptome, but additional USP7 functions also impact proliferation to a lesser extent. Finally, I used parallel experimental and computational approaches with pharmacological and genetic tools coupled with multiple, publicly available omics datasets to systematically interrogate the function and therapeutic potential of each DUB (chapter IV), and these results comprise the majority of the work presented here. I use this multi-omics approach to identify candidate functions and interactors essential for proliferation for 35 DUBs and investigate the transcriptional impacts of DUB knock out and inhibition. Overall, in this thesis, I present novel insights into both well studied DUBs as well as understudied DUBs, identify promising therapeutic contexts for many individual DUBs, and create a resource of integrated omics datasets for further exploration of DUB function. For example, I determine that copy number loss of USPL1 is predictive of sensitivity to USPL1 loss and the role of USPL1 in the Little Elongation Complex is central to its impact on cancer cell proliferation and transcription.

ISBN: 9798496528863Subjects--Topical Terms:

708586
Systematic biology.
Subjects--Index Terms:

Bioinformatics

Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology.
LDR:03536nmm a2200397 4500 001 616472
005 20220513114346.5
008 220920s2021 ||||||||||||||||| ||eng d
020 $a 9798496528863
035 $a (MiAaPQ)AAI28720041
035 $a AAI28720041
040 $a MiAaPQ $c MiAaPQ
100 1 $a Doherty, Laura. $0 (orcid)0000-0002-8171-5109 $3 915811
245 1 0 $a Characterization of the Functions and Therapeutic Potential of Deubiquitinating Enzymes in Oncology.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 186 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-05, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisor: Sorger, Peter;Buhrlage, Sara.
502 $a Thesis (Ph.D.)--Harvard University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a DUBs are dysregulated in cancer and other diseases, but there is much that is unknown about the specific substrates and pathways that individual DUBs regulate and their clinical utility remains incompletely explored. In this work, I present characterization of the functions and therapeutic potential of DUBs in oncology through pharmacological and genetic studies coupled with analysis of publicly available datasets. First, I used phenotypic screens using early small molecule DUB inhibitors and target deconvolution to identify promising DUB targets in acute myeloid leukemia (AML) and breast cancer (chapter II). Specifically, I identify USP10 as the DUB responsible for stabilizing the oncoprotein, FMS-like receptor tyrosine kinase-3 (FLT3), in AML, and I identify USP7 as a DUB with selective proliferative effects based on subtype in breast cancer. Next, I used targeted studies with USP7 inhibitors to understand the functions of USP7 important for transcription and proliferation as well as characterize the polypharmacology of commonly used USP7 inhibitors. (chapter III). I conclude that p53 is central to the impact of USP7 on both proliferation and the transcriptome, but additional USP7 functions also impact proliferation to a lesser extent. Finally, I used parallel experimental and computational approaches with pharmacological and genetic tools coupled with multiple, publicly available omics datasets to systematically interrogate the function and therapeutic potential of each DUB (chapter IV), and these results comprise the majority of the work presented here. I use this multi-omics approach to identify candidate functions and interactors essential for proliferation for 35 DUBs and investigate the transcriptional impacts of DUB knock out and inhibition. Overall, in this thesis, I present novel insights into both well studied DUBs as well as understudied DUBs, identify promising therapeutic contexts for many individual DUBs, and create a resource of integrated omics datasets for further exploration of DUB function. For example, I determine that copy number loss of USPL1 is predictive of sensitivity to USPL1 loss and the role of USPL1 in the Little Elongation Complex is central to its impact on cancer cell proliferation and transcription.
590 $a School code: 0084.
650 4 $a Systematic biology. $3 708586
650 4 $a Bioinformatics. $3 194415
650 4 $a Cellular biology. $3 708607
653 $a Bioinformatics
653 $a Cancer
653 $a CRISPR
653 $a Dependency map
653 $a Deubiquitinating enzyme
653 $a Inhibitor
690 $a 0423
690 $a 0715
690 $a 0379
710 2 $a Harvard University. $b Chemical Biology. $3 915812
773 0 $t Dissertations Abstracts International $g 83-05B.
790 $a 0084
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28720041